Ulcerative Colitis | Treatment Algorithms | Claims Data Analysis | US | 2014
As more biologics are approved to treat ulcerative colitis (UC), it is important to analyze the changes in gastroenterologists’ prescribing behaviors. This report uses national patient-level claims data to explore the use of key therapies in newly diagnosed UC patients with a quantitative analysis of treatment patterns and share by line of therapy, as well as progression between lines, duration of treatment on each line, and use of concomitant treatment. Among recently treated patients, we quantify a drug’s source of business compared with its competitors and details which drugs precede others through an analysis of add-versus-switch patterns. Additional analyses explore persistency and compliance by brand.
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious renal and CNS manifestations…
Report
Chronic Kidney Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Kidney Disease (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises therapies, which are…
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
